.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,304,391

« Back to Dashboard

Details for Patent: 8,304,391

Title:Peptides that bind to the erythropoietin receptor
Abstract: Peptide compounds that are agonists of the erythropoietin receptor (EPO-R) are described, as well as therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
Inventor(s): Holmes; Christopher P. (Saratoga, CA), Yin; Qun (Palo Alto, CA), Lalonde; Guy (Woodside, CA), Schatz; Peter J. (Cupertino, CA), Tumelty; David (San Diego, CA), Palani; Balu (Cupertino, CA), Zemede; Genet (San Jose, CA)
Assignee: Affymax, Inc. (Palo Alto, CA)
Filing Date:Mar 17, 2009
Application Number:12/405,599
Claims:1. A method for treating a patient having a deficiency of erythropoietin or a low or defective red blood cell population, which method comprises administering to the patient a therapeutically effective amount of a peptide comprising about 17 to about 40 amino acid residues in length and comprising the amino acid sequence: LYACHX.sub.0GPITX.sub.1VCQPLR (SEQ ID NO: 1), wherein X.sub.0 is a residue selected from the group consisting of methionine (M) and homoserine methylether (Hsm), and X.sub.1 is a residue selected from tryptophan (W), 1-naphthylalanine (1-nal), and 2-naphthylalanine (2-nal).

2. The method according to claim 1, wherein the patient has a disorder selected from the group consisting of: end stage renal failure or dialysis; anemia associated with AIDS, auto immune disease or a malignancy; beta-thalassemia; cystic fibrosis; early anemia of prematurity; anemia associated with chronic inflammatory disease; spinal cord injury; acute blood loss; aging; and neoplastic disease states accompanied by abnormal erythropoiesis.

3. The method according to claim 1, wherein the peptide comprises an amino acid sequence selected from the group consisting of: TABLE-US-00009 (SEQ ID NO: 2) LYACHMGPITWVCQPLR; (SEQ ID NO: 3) LYACHMGPIT(1-nal)VCQPLR; (SEQ ID NO: 4) LYACHMGPIT(2-nal)VCQPLR; (SEQ ID NO: 5) GGLYACHMGPITWVCQPLRG; (SEQ ID NO: 6) GGLYACHMGPIT(1-nal)VCQPLRG; (SEQ ID NO: 7) GGLYACHMGPIT(2-nal)VCQPLRG; (SEQ ID NO: 8) (AcG)GLYACHMGPITWVCQPLRG; (SEQ ID NO: 9) (AcG)GLYACHMGPIT(1-nal)VCQPLRG; (SEQ ID NO: 10) (AcG)GLYACHMGPIT(2-nal)VCQPLRG; (SEQ ID NO: 11) GGLYACHMGPITWVCQPLR(MeG); (SEQ ID NO: 12) GGLYACHMGPIT(1-nal)VCQPLR(MeG); (SEQ ID NO: 13) GGLYACHMGPIT(2-nal)VCQPLR(MeG); (SEQ ID NO: 14) (AcG)GLYACHMGPITWVCQPLRG(MeG); (SEQ ID NO: 15) (AcG)GLYACHMGPIT(1-nal)VCQPLRG(MeG); (SEQ ID NO: 16) (AcG)GLYACHMGPIT(2-nal)VCQPLRG(MeG); (SEQ ID NO: 17) LYACH(Hsm)GPITWVCQPLR; (SEQ ID NO: 18) LYACH(Hsm)GPIT(1-nal)VCQPLR; (SEQ ID NO: 19) LYACH(Hsm)GPIT(2-nal)VCQPLR; (SEQ ID NO: 20) GGLYACH(Hsm)GPITWVCQPLRG; (SEQ ID NO: 21) GGLYACH(Hsm)GPIT(1-nal)VCQPLRG; (SEQ ID NO: 22) GGLYACH(Hsm)GPIT(2-nal)VCQPLRG; (SEQ ID NO: 23) (AcG)GLYACH(Hsm)GPITWVCQPLRG; (SEQ ID NO: 24) (AcG)GLYACH(Hsm)GPIT(1-nal)VCQPLRG; (SEQ ID NO: 25) (AcG)GLYACH(Hsm)GPIT(2-nal)VCQPLRG; (SEQ ID NO: 26) GGLYACH(Hsm)GPITWVCQPLR(MeG); (SEQ ID NO: 27) GGLYACH(Hsm)GPIT(1-nal)VCQPLR(MeG); (SEQ ID NO: 28) GGLYACH(Hsm)GPIT(2-nal)VCQPLR(MeG); (SEQ ID NO: 29) (AcG)GLYACH(Hsm)GPITWVCQPLRG(MeG); (SEQ ID NO: 30) (AcG)GLYACH(Hsm)GPIT(1-nal)VCQPLRG(MeG); and (SEQ ID NO: 31) (AcG)GLYACH(Hsm)GPIT(2-nal)VCQPLRG(MeG).

4. The method according to claim 1, wherein the peptide is a monomer.

5. The method according to claim 1, wherein the peptide is a dimer.

6. The method according to claim 5, wherein the peptide is a homodimer.

7. The method according to claim 1, wherein one or more water soluble polymers are covalently bound to the peptide.

8. The method according to claim 7, wherein the water soluble polymer is polyethylene glycol (PEG).

9. The method according to claim 8, wherein the PEG is a linear unbranched PEG having a molecular weight of about 500 to about 60,000 Daltons.

10. The method according to claim 9, wherein the PEG has a molecular weight of about 500 to less than about 20,000 Daltons.

11. The method according to claim 9, wherein the PEG has a molecular weight of about 20,000 to 60,000 Daltons.

12. The method according to claim 11, wherein the PEG has a molecular weight of about 20,000 to about 40,000 Daltons.

13. The method according to claim 8, wherein two PEG moieities are covalently bound to the peptide, each of said PEG comprising a linear unbranched molecule.

14. The method according to claim 13, wherein each of said PEG has a molecular weight of about 20,000 to about 30,000 Daltons.

15. A method for stimulating erythropoiesis in a patient, which method comprises administering to the patient an effective amount of a peptide comprising about 17 to about 40 amino acid residues in length and comprising the amino acid sequence: TABLE-US-00010 LYACHX.sub.0GPITX.sub.1VCQPLR, (SEQ ID NO: 1)

wherein X.sub.0 is a residue selected from the group consisting of methionine (M) and homoserine methylether (Hsm), and X.sub.1 is a residue selected from the group consisting of tryptophan (W), 1-naphthylalanine (1-nal), and 2-naphthylalanine (2-nal).

16. The method according to claim 15, wherein the patient has a deficiency in erythropoietin or a low or defective red blood cell population.

17. The method according to claim 16, wherein the patient has a disorder selected from the group consisting of: end stage renal failure or dialysis; anemia associated with AIDS, auto immune disease or a malignancy; beta-thalassemia; cystic fibrosis; early anemia of prematurity; anemia associated with chronic inflammatory disease; spinal cord injury; acute blood loss; aging; and neoplastic disease states accompanied by abnormal erythropoiesis.

18. The method according to claim 15, wherein the peptide comprises an amino acid sequence selected from the group consisting of: TABLE-US-00011 (SEQ ID NO: 2) LYACHMGPITWVCQPLR; (SEQ ID NO: 3) LYACHMGPIT(1-nal)VCQPLR; (SEQ ID NO: 4) LYACHMGPIT(2-nal)VCQPLR; (SEQ ID NO: 5) GGLYACHMGPITWVCQPLRG; (SEQ ID NO: 6) GGLYACHMGPIT(1-nal)VCQPLRG; (SEQ ID NO: 7) GGLYACHMGPIT(2-nal)VCQPLRG; (SEQ ID NO: 8) (AcG)GLYACHMGPITWVCQPLRG; (SEQ ID NO: 9) (AcG)GLYACHMGPIT(1-nal)VCQPLRG; (SEQ ID NO: 10) (AcG)GLYACHMGPIT(2-nal)VCQPLRG; (SEQ ID NO: 11) GGLYACHMGPITWVCQPLR(MeG); (SEQ ID NO: 12) GGLYACHMGPIT(1-nal)VCQPLR(MeG); (SEQ ID NO: 13) GGLYACHMGPIT(2-nal)VCQPLR(MeG); (SEQ ID NO: 14) (AcG)GLYACHMGPITWVCQPLRG(MeG); (SEQ ID NO: 15) (AcG)GLYACHMGPIT(1-nal)VCQPLRG(MeG); (SEQ ID NO: 16) (AcG)GLYACHMGPIT(2-nal)VGQPLRG(MeG); (SEQ ID NO: 17) LYACH(Hsm)GPITWVCQPLR; (SEQ ID NO: 18) LYACH(Hsm)GPIT(1-nal)VCQPLR; (SEQ ID NO: 19) LYACH(Hsm)GPIT(2-nal)VCQPLR; (SEQ ID NO: 20) GGLYACH(Hsm)GPITWVCQPLRG; (SEQ ID NO: 21) GGLYACH(Hsm)GPIT(1-nal)VCQPLRG; (SEQ ID NO: 22) GGLYACH(Hsm)GPIT(2-nal)VCQPLRG; (SEQ ID NO: 23) (AcG)GLYACH(Hsm)GPITWVCQPLRG; (SEQ ID NO: 24) (AcG)GLYACH(Hsm)GPIT(1-nal)VCQPLRG; (SEQ ID NO: 25) (AcG)GLYACH(Hsm)GPIT(2-nal)VCQPLRG; (SEQ ID NO: 26) GGLYACH(Hsm)GPITWVCQPLR(MeG); (SEQ ID NO: 27) GGLYACH(Hsm)GPIT(1-nal)VCQPLR(MeG); (SEQ ID NO: 28) GGLYACH(Hsm)GPIT(2-nal)VCQPLR(MeG); (SEQ ID NO: 29) (AcG)GLYACH(Hsm)GPITWVCQPLRG(MeG); (SEQ ID NO: 30) (AcG)GLYACH(Hsm)GPIT(1-nal)VCQPLRG(MeG); and (SEQ ID NO: 31) (AcG)GLYACH(Hsm)GPIT(2-nal)VCQPLRG(MeG).

19. The method according to claim 15, wherein the peptide is a monomer.

20. The method according to claim 15, wherein the peptide is a dimer.

21. The method according to claim 20, wherein the peptide is a homodimer.

22. The method according to claim 15, wherein one or more water soluble polymers are covalently bound to the peptide.

23. The method according to claim 22, wherein the water soluble polymer is polyethylene glycol (PEG).

24. The method according to claim 23, wherein the PEG is a linear unbranched PEG having a molecular weight of about 500 to about 60,000 Daltons.

25. The method according to claim 24, wherein the PEG has a molecular weight of about 500 to less than about 20,000 Daltons.

26. The method according to claim 24, wherein the PEG has a molecular weight of about 20,000 to 60,000 Daltons.

27. The method according to claim 26, wherein the PEG has a molecular weight of about 20,000 to about 40,000 Daltons.

28. The method according to claim 23, wherein two PEG moieities are covalently bound to the peptide, each of said PEG comprising a linear unbranched molecule.

29. The method according to claim 28, wherein each of said PEG has a molecular weight of about 20,000 to about 30,000 Daltons.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc